Samaresh Sau

Dr. Samaresh Sau is an Assistant Professor (Research) in the Department of Pharmaceutical Sciences atWayne State University, Detroit, MI. In addition, Dr. Sau is an affiliate Member Molecular Therapeutics (MT) Program at Barbara Ann Karmanos Cancer Institute. For more than 11 years, Dr. Sau has been developing potent biomarker-targeted nanoparticles, small molecules, and antibody-drug conjugates for the therapeutic benefit of cancer. Dr. Sau completed his Ph.D. from India's premier research...See more

Dr. Samaresh Sau is an Assistant Professor (Research) in the Department of Pharmaceutical Sciences atWayne State University, Detroit, MI. In addition, Dr. Sau is an affiliate Member Molecular Therapeutics (MT) Program at Barbara Ann Karmanos Cancer Institute. For more than 11 years, Dr. Sau has been developing potent biomarker-targeted nanoparticles, small molecules, and antibody-drug conjugates for the therapeutic benefit of cancer. Dr. Sau completed his Ph.D. from India's premier research Institute, CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad, India. Then,he undertook his first postdoctoral fellowship in the Department of Chemistry at Purdue University to work with Prof. Philip S. Low, a pioneer of biomarker-targeted drug development. Working with Prof. Low and his company (Endocyte acquired by Novartis), he has been exposed and master-skilled to the process of developing clinically translatable biomarker-targeted therapeutics of cancers. Dr. Sau is the author of about 50 publications, 4 book chapters, and inventor of 2-pending patent applications. In addition, Dr. Sau is the Co-I/PI of the department of defense (DoD), National Institute of Health (NIH), and Michigan State Technology Commercialization (MTRAC) and Burroughs Wellcome Fund (BWF)-CRTG grant funding. Dr. Sau's future research objective is to develop potent targeted therapeutic and diagnostic agents for clinical translation in cancer. See less